乌鸦传媒

POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival

But combination may be appropriate for shrinking tumors before surgery

Second-line T-DXd best option in patients with and without intracranial activity, experts says

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease

Time to radiographic progression doubled with ¹⁷⁷Lu-PSMA-617

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

Adjuvant alectinib reduces disease-free survival hazard by 76%

Still some unanswered questions about benefit over other drug regimens, expert says

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

PFS doubled and OS improved, driven by mismatch repair-deficient disease

Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy

Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses